Author

@Biomaven Biomaven

Named biotech specialist who handicaps drug catalysts via clinical depth and patent law

Posts original, deeply reasoned biotech/pharma analysis — cl

trader score
+1.72
hit rate
60%
mean α
+1.57%
signals 14d
10

Grade = how their written analysis reads (A best). Trader score = how their last-20 timestamped calls performed vs SPY.

Their picks, scored

Across their last 20 scored bets: 60% hit rate, +1.57% mean alpha, trader score +1.72. Their last-14d mentions, direction-adjusted, have moved -5.6% since posting (mean over 4 mentions with price data).

Recent signals10receipts included
date (PT)tickerauthorsentwhat they saidsince thenreceipt
2026-07-02PBA@Biomaven+0.45Discloses owning PBA as long-term Canadian energy play expected to benefit from Gulf crisis.·
2026-06-30·@Biomaven·Predicts Europe will impose tariffs on Chinese car imports, without a named public ticker.·
2026-06-27·@Biomaven·General portfolio tax-loss and winner-management commentary without tickers.·
2026-06-25·@Biomaven·General valuation discipline statement without tickers.·
2026-06-24MSTR@Biomaven-0.65Author says MSTR has been an easy short and becomes expensive leveraged BTC without premium.+7.1%
2026-06-24BTC@Biomaven+0.00Author says MSTR has been an easy short and becomes expensive leveraged BTC without premium.·
2026-06-22QQQ@Biomaven+0.20Author notes QQQ has outpaced XBI, while skeptical of charting.-3.4%
2026-06-22XBI@Biomaven-0.20Author notes QQQ has outpaced XBI, while skeptical of charting.+10.0%
2026-06-22·@Biomaven·Author expects several unnamed biotechs to be acquired by big pharma over five years.·
2026-06-22TGTX@Biomaven+0.75Author says TGTX subQ Briumvi case remains strong and calls it an easy buy and hold.-2.0%

Grade is our human read-worthiness rating; trader score is a rolling 20-bet hit-rate/alpha composite — different things, often disagreeing. “Since then” is direction-unaware in the table; the summary line above adjusts for which way they leaned.